CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
General Medicine banks $120M backed by a16z, Eli Lilly and Mercy Health to build out healthcare storefront

From Fierce Healthcare

By Heather Landi

October 7, 2026

General Medicine banks $120M backed by a16z, Eli Lilly and Mercy Health to build out healthcare storefront

General Medicine banks $120M backed by a16z, Eli Lilly and Mercy Health to build out healthcare storefront
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
  • Providers
    • Hospitals
    • Practices
    • Retail
  • Health Tech
    • AI and Machine Learning
    • Digital Health
    • Telehealth
  • Payers
  • Regulatory
  • Finance
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • DEI Awards
    • Innovation Awards
  • Resources
    • Webinars
    • Fierce Events
    • Industry Events
    • Podcasts
    • Survey
    • Whitepapers
  • Events
  • Providers
    • Hospitals
    • Practices
    • Retail
  • Health Tech
    • AI and Machine Learning
    • Digital Health
    • Telehealth
  • Payers
  • Regulatory
  • Finance
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • DEI Awards
    • Innovation Awards
  • Resources
    • Webinars
    • Fierce Events
    • Industry Events
    • Podcasts
    • Survey
    • Whitepapers
  • Events
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
On "Podnosis": New rules for healthcare’s flexible workforce
Health Tech
By Heather Landi Oct 7, 2026 2:00pm
General Medicine Andreessen Horowitz Mercy Health Eli Lilly

Artificial intelligence is making healthcare advice easier to access, but turning that advice into actual care remains a challenge.

While many healthcare companies are building AI assistants that can tell patients what care they might need, few have built the underlying marketplace and fulfillment layer required to deliver that care.

Startup General Medicine aims to bridge that gap by connecting healthcare recommendations to actual care, whether that means filling a prescription, ordering a lab test, scheduling a telehealth visit or booking an in-person appointment.

Consumers need a healthcare store, asserts TJ Parker, co-founder of General Medicine. 

"We're entering a world where advice is abundant, but acting on it is still an enormous hassle. General Medicine makes it easy to get guidance from a clinician, shop for care, and see what it will cost before deciding," he said.

General Medicine announced Tuesday that it picked up $120 million in series B funding to build out its "healthcare store" and expand into more categories of care. 

Andreessen Horowitz (a16z) led the round with participation from Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management and BoxGroup. A year ago, the company picked up $32 million in venture capital funding led by Matrix, BoxGroup, the Founder Collective, VXI Capital and JSL Ventures. The company has raised $152 million to date.

General Medicine, started by the founding team that built PillPack and Amazon Pharmacy, is an online marketplace where customers can search, compare and buy care, see insurance and cash prices before deciding, and get guidance from a licensed clinician. The platform connects consumers to providers to either address specific medical needs or to chat about the symptoms they're having.

screenshot of General Medicine's healthcare store

The company's executives refer to it as a "one-stop shop" for telemedicine, prescriptions, imaging, labs and specialists. Parker and PillPack co-founder Elliot Cohen teamed up with former Amazon executive Ashwin Muralidharan to get General Medicine off the ground in the fall of 2023.

After serving on General Medicine's board since the company's founding, Parker has now jumped in full-time as CEO. Muralidharan moved into the chief product officer role and Cohen serves as president. Before joining full-time, Parker was a general partner at Matrix, where he led General Medicine's early funding rounds. 

General Medicine is seeing strong customer traction, Parker said, attracting "hundreds of thousands" of customers across every state and nearly every county, with users spanning commercial insurance, Medicare and Medicaid, he noted.

The majority of users, about 83%, say the company helped them address a health need they had been putting off; a third had delayed care for more than six months.

The company's product catalog now includes more than 2,900 products and services across medications, labs, telehealth and select in-person visits and procedures. General Medicine is expanding its healthcare marketplace gradually, starting with simpler, more standardized services such as pharmacy and lab testing before tackling more complex procedures, Parker noted. The company plans to broaden its catalog to include imaging and a wider range of outpatient procedures.

General Medicine built its healthcare marketplace around a standardized catalog that translates how patients, clinicians, insurers and providers describe the same healthcare service, making it easier to compare options, prices and care pathways, executives said.

Consumers can access care through direct shopping, clinician consultations or an AI chat interface, with their health history and context following them across each channel. A licensed clinician determines what is clinically appropriate whenever clinical review is required, according to executives. General Medicine gathers an average of 11 years of health history for each customer, and that's presented to clinicians as a prioritized summary at the time of care. 

The same infrastructure that supports consumers today is designed to eventually enable AI agents to search for and purchase healthcare services on a patient's behalf, according to executives.

Related

From PillPack to digital health, how General Medicine's founders are building a healthcare storefront

Parker, a second-generation pharmacist, co-founded e-commerce pharmacy PillPack along with Cohen, which Amazon bought in 2018 in a $750 million deal. Parker and Cohen helped build Amazon Pharmacy, which was born out of the PillPack acquisition, as well as Amazon Clinic.

Parker says there were lessons from his work at PillPack and Amazon about making healthcare more convenient, accessible and a more enjoyable experience. But he also sees distinct differences between what General Medicine is building and Amazon Health, which has the online pharmacy business, One Medical concierge primary care and Amazon One Medical pay-per-visit telehealth services (formerly Amazon Clinic).

"We have really focused on this concept of a product catalog, which I think is a big unlock for customers' ability to actually shop and navigate healthcare. What the catalog ultimately does is it connects the need that a customer has with the system that exists today, and so enables us to have really precise intake, so that the customer can actually share everything they need with the clinician before a visit, the clinician is prepared for the visit and then it actually aligns everything that happens in the backend with that need," Parker said.

He added, "You take things like CPT codes, which historically were never designed to turn into a customer-facing price, and create this product catalog that allows us to align all these backend systems with the ways customers think about the offering."

The company also aims to bring together pricing data that has traditionally been fragmented, allowing consumers to compare both insurance-based and cash-pay costs side by side before making healthcare decisions.

General Medicine offers a broader range of products and services than most telehealth companies and other online healthcare marketplaces, Parker contends. "I think the last generation of telemedicine, by and large, have been very vertically focused on a couple of conditions or a very specific clinical focus. We intentionally want customers to be able to come to us for absolutely anything, and we don't constrain the types of services that we can get them access to," he said.

Consumers can shop for care from General Medicine's own medical group or connect with clinicians and healthcare organizations across the country, throughout the same storefront. 

"We can get you to any provider that you want to see. We're not constraining who you can access based on us having a deep integration with them or a financial relationship. The goal is that if a customer wants to go see a provider that's local, we facilitate the referral, we administratively handle booking them the appointment, and in that process, it's very obvious who's in and out of network and what your out-of-pocket cost is going to be to see that provider. The goal is to get customers access to the care that is best for them without constraining that," Parker said.

Along with attracting venture capital investors, General Medicine's series B round was supported by two legacy healthcare incumbents, Eli Lilly and Mercy Health, through institutional investor Granger Management. 

General Medicine and Eli Lilly are aligned on reorienting healthcare and pharmacy around the end customers, Parker said. The pharma giant launched LillyDirect in 2024 as the first major drugmaker to offer a direct-to-consumer model.

Regarding Mercy Health's participation in the funding round, Parker said, "Given our ambition is to create this continuity to traditional offline care, we felt super aligned that they would be a really interesting partner to try to figure out exactly how that works and what that looks like for customers to go seamlessly from a digital storefront all the way through to an offline procedure or visit."

Vineeta Agarwala, M.D., Ph.D., general partner at a16z, who led the investment, said in a statement, "General Medicine has built one of the best patient experiences we've seen in the market. One-click, comprehensive medical record collection, same-day specialist visits, prescriptions delivered to your door: the team has meticulously designed and built the core scaffold for almost every consumer healthcare product we could imagine. We can't wait to see this scale to patients seeking all kinds of care."

General Medicine's co-founders believe giving patients greater visibility into costs and choices will lead to a more consumer-driven healthcare market and create stronger incentives for providers, payers and manufacturers to compete for their business.

Parker rejected the notion that insurers, rather than patients, are the true customers in healthcare. 

When consumers are shown clear side-by-side comparisons of insurance and cash prices, many choose the option that offers the best value, he noted.

"Ultimately, the customer is the one receiving care. At the end of the day, they are the ones deciding where to go and what to get, obviously alongside the clinician. I think we will prove that you can make the customer the actual decision-maker here, and that will shift the centers of power and the incentives," Parker said.

General Medicine Andreessen Horowitz Mercy Health Eli Lilly Consumer health PillPack Amazon funding round venture capital (VC) AI and Machine Learning Digital Health Finance Retail Health Tech
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
    • Editorial Advisory Council
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
Terms of use
Privacy Policy
Privacy Settings

View original article on fiercehealthcare.com

Most Recent

Anthropic and OpenAI have pushed for substantial control over what external AI evaluators can publish, out of concern that trade secrets could leak

Anthropic and OpenAI have sought significant control over what outside evaluators can publish, concerned that findings could reveal trade secrets …

Oct 13, 2026

How crypto billionaires Christopher Harborne, who owns ~12% of Tether, and Ben Delo donated ~$100M to Nigel Farage's Reform, the largest donations in UK history

For a pub-going, cigarette-puffing man of the people, Nigel Farage, the leader of the Reform U.K. party, sure has some very rich friends.

Oct 13, 2026

Accenture's market cap rebounded from $76B in June to ~$130B ahead of its investor day, where it seeks to reassure investors that AI won't threaten its business

The technology consultancy seeks to calm jitters with an investor day this week — In the space of three months …

Oct 13, 2026

Alibaba Unveils $450 AI Glasses in Expanding Push Into Gadgets

Alibaba Group Holding Ltd. on Tuesday unveiled the new generation of its smart glasses, deepening its foray into consumer electronics …

Oct 13, 2026

Similar Posts

AI, Tech Leaders Are Lobbying Trump Health Officials in a Government-Run Chat Room

A Slack workspace managed by the Centers for Medicare & Medicaid Services has served as an extraordinary war room for AI industry insiders and Trump administration officials to launch a rapid campaign aimed at persuading Americans to manage their healthcare and medical records on apps.

Oct 9, 2026

Hippocratic is building a large language model for healthcare

AI, specifically generative AI, has the potential to transform healthcare. At least, that sales pitch from Hippocratic Health, which emerged from stealth today with a whopping $50 million in seed financing behind it and a valuation in the “triple digit millions.” The tranche, co-led by General Catalyst and Andreessen Horowitz, is a big vote of […]

May 16, 2023

General Medicine raises $120 million to expand healthcare store By Investing.com

General Medicine raises $120 million to expand healthcare store

Oct 6, 2026

General Medicine Raises $120 Million to Build the Healthcare Store

Customers nationwide can search, compare, and buy care, seeing upfront what it costs with and without insurance.

Oct 6, 2026